REFERENCES
1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. ; 2019.
2. Stephen P. Hunger, M.D., and Charles G. Mullighan MD. Acute Lymphoblastic Leukemia in Children. N Engl J Med . 2015;373:1541-1552.
3. Kiem Hao T, Nhu Hiep P, Kim Hoa NT, Van Ha C. Causes of Death in Childhood Acute Lymphoblastic Leukemia at Hue Central Hospital for 10 Years (2008-2018). Glob Pediatr Heal . Published online 2020.
4. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet . Published online 2003.
5. Hoang PTV, Ambroise J, Chi VLD, et al. Comparison of long-term outcome between white and Vietnamese children treated for acute lymphoblastic leukemia according to the FRALLE 2000 protocol. J Pediatr Hematol Oncol . Published online 2014.
6. Yeoh A, Tan D, Li C-K, Hori H, Tse E, Pui C-H. Oncology Summit 2013.Lancet Oncol . Published online 2014.
7. Karachunskiy A, Herold R, von Stackelberg A, et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia . 2008;22(6).
8. Yeoh AEJ, Ariffin H, Chai ELL, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: Results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol . Published online 2012.
9. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood . Published online 2008.
10. Park KD, Hong CR, Choi JY, et al. Foundation of pediatric cancer treatment in Lao People’s Democratic Republic at the Lao-Korea National Children’s Hospital. Pediatr Hematol Oncol . Published online 2018.
11. Mostert S, Sitaresmi MN, Gundy CM, Sutaryo, Veerman AJP. Influence of socioeconomic status on childhood acute lymphoblastic leukemia treatment in Indonesia. Pediatrics . Published online 2006.
12. Sitaresmi MN, Mostert S, Schook RM, Sutaryo, Veerman AJP. Treatment refusal and abandonment in childhood acute lymphoblastic leukemia in Indonesia: An analysis of causes and consequences.Psychooncology . Published online 2010.
13. Navarrete M, Rossi E, Brivio E, et al. Treatment of childhood acute lymphoblastic leukemia in central America: A lower-middle income countries experience. Pediatr Blood Cancer . Published online 2014.
14. Advani S, Pai S, Venzon D, et al. Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen. Ann Oncol . Published online 1999.
15. Pedrosa F, Coustan-Smith E, Zhou Y, et al. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: Long-term results of the Recife RELLA05 pilot study. Blood . Published online 2020.
16. Sidhom I, Shaaban K, Youssef SH, et al. Reduced-intensity therapy for pediatric lymphoblastic leukemia: Impact of residual disease early in remission induction. Blood . Published online 2021.
17. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol . Published online 2009.
18. Hamadeh L, Enshaei A, Schwab C, et al. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Adv . Published online 2019.
19. Logan C, Koura D TR. Updates in infection risk and management in acute leukemia. Hematol Am Soc Hematol Educ Progr . 2020;2020(1):135-139.
20. Brown PA, Ji L, Xu X, et al. A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Eff. Blood . 2019;134(Supplement_2):LBA-1-LBA-1.